One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition.
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.
“Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled ‘orphan diseases.’ We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases,” said Misagh Naderi, one of the paper’s lead authors and a doctoral candidate in the LSU Department of Biological Sciences.
This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.
“In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson’s disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease,” said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.
The Latest on: Drug repositioning
via Google News
The Latest on: Drug repositioning
- Coronavirus deaths top 10,000 globallyon March 19, 2020 at 7:37 pm
The novel coronavirus has sent countries worldwide under lockdown and threatened the global economy. Follow here for live updates.
- Drug Reduxon March 18, 2020 at 5:00 pm
Oct. 10, 2007 | Call it what you will, extracting value from well-studied compounds that bind an interesting drug target, have drug-like characteristics, and offer an attractive safety and ...
- A scientist's perspective on the COVID-19 pandemicon March 18, 2020 at 6:53 am
Typically, it can take five to 10 years to bring a new drug to the market. However, the approach we are taking at Sanford Burnham Prebys, known as drug repositioning, can cut this development time ...
- What is the efficacy of canalith repositioning (CRP) for the treatment of benign paroxysmal positional vertigo (BPPV)?on March 12, 2020 at 5:00 pm
Is drug consumption correlated with benign paroxysmal ... Tirelli G, Nicastro L, Gatto A, Tofanelli M. Repeated canalith repositioning procedure in BPPV: Effects on recurrence and dizziness ...
- Robots and AI deployed to fight against coronaviruson March 12, 2020 at 5:14 am
Drug repositioning, or drug repurposing, which seeks to find new therapeutic uses for existing drugs, is also being explored. "It will take time to develop drugs against COVID-19. However, [the] drug ...
- Renewed Purpose for Drug Repositioningon March 8, 2020 at 5:00 pm
A number of speakers at CHI’s second annual Drug Repositioning Summit* quoted that memorable phrase, which begged the question that Chris Lipinski, the former Pfizer chemist of “Rule-of-Five” fame, ...
- Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Dataon March 4, 2020 at 4:00 pm
The application of established drug compounds to new therapeutic indications, known as drug repositioning, offers several advantages over traditional drug development, including reduced development ...
- Coronavirus Treatment Could Lie in Existing Drugson February 27, 2020 at 6:21 am
The researchers suggest that repositioning existing approved and investigational drugs may represent the key to future fights against viral infections — including the SARS-CoV-2 virus ...
- Cancer research: Could drugs already on the market provide a cure?on February 4, 2020 at 9:59 am
Saving time and expense Oncology researchers are now focusing on "drug repositioning" as they search for cures for cancer. The advantages of this approach: The lengthy research and approval ...
- Matchmaking service links up researchers to wallflower drugson August 24, 2018 at 3:54 pm
And Pfizer is ahead of other pharmaceutical firms, many of which are just initiating drug-repositioning programs. To overcome some of the barriers, Marusina and her colleagues plan to develop a ...
via Bing News